首页> 中文期刊> 《南京中医药大学学报》 >运脾柔肝方对便秘型肠易激综合征大鼠5-HT、VIP及SP影响的实验研究

运脾柔肝方对便秘型肠易激综合征大鼠5-HT、VIP及SP影响的实验研究

         

摘要

OBJECTIVE To observe the effects of Yunpi Rougan Fang on serum and colon tissue serum serotonin(5-HT),vasoactive peptide(VIP)and substance P(SP)in constipation-predominant irritable bowel syndrome rats,to explore its possi-ble mechanism and relevance.METHODS 42 SPF Wistar rats,Six rats were randomly selected as normal group,the remai-ning 36 rats were modeled by ice water for 14 d,evaluation model,30 rats were randomly selected and randomly divided into Chinese medicine high,medium and low dose group,western medicine group,model control group,each group had 6 rats.The Chinese medicine low,middle and high dose groups were treated with 12.2,24.4,48.8 g/(kg·d),Mosapride group with moxapril suspension 1.35 mg/(kg·d)gavage,model control group and blank group were given equal amount of distilled water to fill the stomach.After 14 d,the levels of 5-HT,VIP and SP in the serum and the levels of 5-HT and VIP in the colon tissue were measured.RESULTS Compared with the blank group,the expression of 5-HT and VIP in serum and colon tissue immu-nization in the model control group was increased significantly(P0.01),the expression of SP in serum was decreased(P0.05).Different doses can decrease the levels of serum 5-HT and VIP in C-IBS model rats(P0.01),significantly increased the serum SP level(P0.05).Immunohistochemical results showed that the expression of 5-HT in colon tissue was signifi-cantly decreased(P0.05),and the expression of VIP was significantly decreased(P0.01).Although the expression of each treatment group no significant difference(P >0.05),from the numerical changes,Yunpi Rougan Fang was superior to mosapride and showed dose-dependency.CONCLUSION Yunpi Rougan Fang can obviously improve the symptoms of constipation in C-IBS model rats,by reducing the expression of 5-HT and VIP,improving the expression of SP to regulate intestinal function,which plays a therapeutic role in C-IBS.%目的 通过观察运脾柔肝方对便秘型肠易激综合征(C-IBS)模型大鼠血清、肠组织5-羟色胺(5-HT)、血管活性肠肽(VIP)、P物质(SP)的影响,探讨运脾柔肝方对C-IBS模型大鼠的可能作用机制.方法 将42只 Wistar大鼠,随机选取6只作为正常组,剩余36只大鼠采用冰水灌胃法造模14 d,评价模型,随机选取造模成功的30只大鼠,采用随机数字法分为运脾柔肝方中药低、中、高剂量组、莫沙必利组、模型对照组,每组6只.运脾柔肝方低、中、高剂量组分别以12.2、24.4、48.8 g/(kg ·d)的给药剂量灌胃,莫沙必利组以莫沙必利混悬液1.35 mg/(kg·d)灌胃,模型对照组及空白组给予等量蒸馏水灌胃.14 d后观察各组大鼠一般情况,并检测各组大鼠血清5-HT、VIP、SP 水平和肠组织5-HT、VIP 的含量.结果 与空白组相比,模型对照组血清、结肠组织免疫组显5-HT、VIP的表达水平较正常组显著升高(P0.01),而血清SP的表达水平则明显降低(P0.05),不同剂量运脾柔肝方均可显著降低C-IBS模型大鼠血清5-HT、VIP的表达水平(P0.01),明显升高大鼠血清SP水平(P0.05),免疫组化结果显示各组均能明显降低5-HT 在肠组织中的表达(P0.05),显著降低 VIP 的表达(P0.01).结论 运脾柔肝方可显著改善C-IBS模型大鼠便秘症状,可能是通过降低5-HT、VIP 和升高 SP 的表达水平,从而调节肠道功能,发挥治疗C-IBS的作用.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号